Association between prescribed central nervous system depressant drugs, comorbidity and cognition among hospitalised older patients: a cross-sectional study
Permanent link
https://hdl.handle.net/10037/18906Date
2020-07-27Type
Journal articleTidsskriftartikkel
Peer reviewed
Author
Siddiqui, Tahreem Ghazal; Cheng, Socheat; Gossop, Michael; Kristoffersen, Espen Saxhaug; Grambaite, Ramune; Lundqvist, ChristoferAbstract
Design - Cross-sectional hospital-based study.
Settings - Data was collected consecutively from inpatients at somatic wards of a general university hospital.
Participants - Older patients between 65 and 90 years with/without CNSD use for ≥4 weeks.
Outcome measures - The main outcome was cognitive function assessed by Cognistat. Secondary outcomes were routine clinical tests in the wards (mini-mental state examination (MMSE), trail making test (TMT) A and B, and clock drawing tests). Analyses were bivariate and multiple linear regression, adjusted for age, gender, and education. Covariates were comorbidity, depression and anxiety scores.
Results - The main result indicated that CNSD users (n=100) had (β=–3.4, 95% CI 6.27 to –0.58, p=0.017) lower Cognistat score than non-users (n=146), adjusted for age, gender, education, anxiety and depression, but not significant when including covariate for comorbidity (β= –2.50 - 5.45; –0.46, p=0.097). Comorbidity was associated with cognitive function (β=−0.77, 95% CI −1.22 to −0.14, p=0.014). Cognistat subdimensions associated with CNSD use were language (p=0.017) and calculation (p=0.003). In clock drawing test, users had lower scores than non-users (β=−0.80, 95% CI 1.24 to −0.36, p=0.004), but no significant difference was found with MMSE and TMT A or B. Z-hypnotics were associated with reduced cognitive function.
Conclusion - Among older hospitalised patients, global cognition and specific cognitive functions were associated with long-term use of CNSD medication as well as with somatic comorbidity.